Oxford BioMedicaLSE:OXB -0.16%68 Median PS Value is £9.95 as of Jun. 27, 2026, which is 100% below its 10-year median of 0.85. GuruFocus rates LSE:OXB with a GF Score™ of 68/100 and a GF Value™ of £5.36 (Modestly Overvalued). The stock has 5 warning signs investors should review. Among 276 Biotechnology companies, Oxford BioMedica ranks worse than 52.17% on this metric.
This valuation method assumes that the stock valuation will revert to its historical (10-Year) median in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.
The historical rank and industry rank for Oxford BioMedica's Median PS Value or its related term are showing as below:
LSE:OXB'
s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.28 Med: 0.85 Max: 1.56
Current: 0.64
During the past 13 years, the highest Price to Median PS Value of Oxford BioMedica was 1.56. The lowest was 0.28. And the median was 0.85.
LSE:OXB's Price-to-Median-PS-Value is ranked worse than 52.17% of 276
companies
in the Biotechnology industry
Industry Median: 0.62
vs LSE:OXB: 0.64
Oxford BioMedica (LSE:OXB) Median PS Value Explanation
This valuation method assumes that the stock valuation will revert to its historical (10-Year) mean in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio
is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.
It also assumes that over time the profit margin is constant. If a company increases its profit margin to a sustainable level, this value might under-estimate its value. If it has permanent declined profit margins, this may over-estimate the company's value.
Oxford BioMedica's Price to Median PS Value for today is calculated as
Price to Median PS Value
=
Share Price
/
Median PS Value
=
6.33
/
9.95
=
0.64
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Oxford BioMedica Median PS Value Related Terms
Oxford BioMedica Median PS Value Historical Data
* Premium members only.
The historical data trend for Oxford BioMedica's Median PS Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LSE:OXB vs VRTX, REGN, ALNY: Median PS Value Comparison
For the Biotechnology subindustry, Oxford BioMedica's Price-to-Median-PS-Value, along with its competitors' market caps and Price-to-Median-PS-Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Oxford BioMedica Price-to-Median-PS-Value vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Oxford BioMedica's Price-to-Median-PS-Value distribution charts can be found below:
* The bar in red indicates where Oxford BioMedica's Price-to-Median-PS-Value falls into.
10-Year Median PS Ratio is 6.6245.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Oxford BioMedica's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2025 was £1.502.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Oxford BioMedica (LSE:OXB) has a Median PS Value of £9.95 as of Jun. 27, 2026. Median price-sales value is the stock value based on a company's 10-year median price-sales ratio, View historical data on Oxford BioMedica and its competitors. This is 1071% above median its historical median of 0.85. Over the past decade, Oxford BioMedica's Median PS Value has ranged from 0.28 to 1.56. According to the industry distribution chart, Oxford BioMedica ranks #144 out of 276 companies in the Biotechnology industry, placing it in the top 52.2%.
Is Oxford BioMedica's Median PS Value too high?
Oxford BioMedica's current Median PS Value of £9.95 is 1071% above median its 10-year median of 0.85. Over the past 10 years, this metric has ranged from a low of 0.28 to a high of 1.56. Based on the distribution chart, Oxford BioMedica ranks #144 out of 276 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Oxford BioMedica has a GF Score™ of 68/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Oxford BioMedica's Median PS Value compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Oxford BioMedica ranks #144 out of 276 companies for Median PS Value. This places Oxford BioMedica in the lower half of its industry. The industry median Median PS Value is 0.62. Historically, Oxford BioMedica's own Median PS Value has ranged from 0.28 to 1.56 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Median PS Value for a Biotechnology company?
The median Median PS Value among Biotechnology companies is 0.62, based on 276 companies in the industry. Companies in the top quartile (top 25%) have a Median PS Value significantly above this median, while those in the bottom quartile fall well below. However, Median PS Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Median PS Value mean?
A high Median PS Value can signal that a stock is expensive relative to its fundamentals. Median price-sales value is the stock value based on a company's 10-year median price-sales ratio, View historical data on Oxford BioMedica and its competitors. For the Biotechnology industry, the median Median PS Value is 0.62 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Oxford BioMedica's current Median PS Value is £9.95, which is 1071% above median its own 10-year median of 0.85. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Oxford BioMedica stock overvalued right now?
Based on GuruFocus' analysis, Oxford BioMedica (LSE:OXB) is currently considered Modestly Overvalued. The stock's GF Value™ is £5.36, compared to a current price of £6.33 — trading 18.1% above its estimated fair value. The current Median PS Value is £9.95, which is 1071% above median its 10-year median of 0.85. Oxford BioMedica's overall GF Score™ is 68/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Median PS Value calculated?
Median PS Value is calculated from a company's financial statements. For Oxford BioMedica (LSE:OXB), the current Median PS Value is £9.95 as of Jun. 27, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Oxford BioMedica (LSE:OXB) Overvalued in 2026?
Based on GuruFocus' analysis, Oxford BioMedica stock appears to be overvalued.
The current stock price of £6.33 is trading 18.1% above its estimated GF Value™ of £5.36.
GuruFocus considers Oxford BioMedica to be Modestly Overvalued.
Key valuation signals for LSE:OXB:
Median PS Value: £9.95 (1071% above median its 10-year median of 0.85)
GF Value™: £5.36 vs. price of £6.33 (18.1% above fair value)
No single metric tells the full story. See the LSE:OXB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Oxford BioMedica PLC is a contract development and manufacturing organization (CDMO) focused on cell and gene therapy. The company specializes in viral vector development and manufacturing for cell and gene therapy, with expertise in lentivirus, adeno-associated virus (AAV), adenovirus, and other viral vector types. Geographically, it derives maximum revenue from the United States, and the rest from Europe, the UK, and the Rest of the world.
68GF Score
Get the complete analysis for LSE:OXB
Median PS Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LSE:OXB has been successfully added to your 
